DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 18-200/S-023
NDA 18-201/S-036

Merck & Co., Inc.
Attention: Mr. Kenneth A. Kramer
Sumneytown Pike
P.O. Box 4, BLA-20
West Point, PA 19486

19 SEP 2001

Dear Mr. Kramer:

Please refer to your supplemental new drug applications dated August 4 and August 3, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Midamor (amiloride HCl) 5 mg Tablets (NDA 18-200) and Moduretic (amiloride HCl/ hydrochlorothiazide) 5/50 mg Tablets (NDA 18-201), respectively.

We acknowledge receipt of your submissions dated July 13, 2001 and August 7, 2001.

These supplemental new drug applications provide for final printed labeling (electronic) with the following revision to the **WARNINGS**/*Hyperkalemia* and **PRECAUTIONS**/*Drug Interactions/Amiloride HCl* sections of the labeling:

> "cyclosporine or tacrolimus" has been added to the list of agents that may increase the risk of hyperkalemia when administered with amiloride HCl.

In addition, we noted minor editorial changes.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the final printed labeling (package insert) included in your August 7, 2001 submission. Accordingly, these supplemental applications are approved effective on the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call:

Mr. Daryl Allis
Regulatory Health Project Manager
(301) 594-5309.

Sincerely,

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research